Target Information

Target General Infomation
Target ID
T94306
Former ID
TTDI01768
Target Name
Integrin alpha-5/beta-1
Target Type
Clinical Trial
Disease Melanoma [ICD9: 172; ICD10: C43]
Non-small cell lung cancer [ICD10: C33-C34]
Ocular disease [ICD10: H00-H59]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Function
Integrin alpha-5/beta-1 is a receptor for fibronectin and fibrinogen. It recognizes the sequence R-G-D in its ligands. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
BioChemical Class
Integrin
UniProt ID
P08648||Q8WUM6
Drugs and Mode of Action
Drug(s) Anti-alpha5Beta1-integrin antibody Drug Info Phase 2 Solid tumours [549992]
Volociximab Drug Info Phase 2 Non-small cell lung cancer [521881]
AMEP Drug Info Phase 1 Melanoma [551212]
F-200 Drug Info Terminated Ocular disease [547693]
Modulator AMEP Drug Info
Inhibitor F-200 Drug Info [550929]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Phagosome
PI3K-Akt signaling pathway
Focal adhesion
ECM-receptor interaction
Hematopoietic cell lineage
Regulation of actin cytoskeleton
Bacterial invasion of epithelial cells
Shigellosis
Pertussis
Proteoglycans in cancer
MicroRNAs in cancer
Hypertrophic cardiomyopathy (HCM)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Dilated cardiomyopathy
Reactome Elastic fibre formation
Fibronectin matrix formation
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Cell surface interactions at the vascular wall
Basigin interactions
Molecules associated with elastic fibres
Integrin cell surface interactions
Laminin interactions
Syndecan interactions
ECM proteoglycans
Other semaphorin interactions
Localization of the PINCH-ILK-PARVIN complex to focal adhesions
CHL1 interactions
RHO GTPases Activate Formins
WikiPathways Focal Adhesion
Extracellular matrix organization
Elastic fibre formation
Arrhythmogenic Right Ventricular Cardiomyopathy
Integrin-mediated Cell Adhesion
L1CAM interactions
Integrin cell surface interactions
Cell surface interactions at the vascular wall
References
Ref 521881ClinicalTrials.gov (NCT00369395) A Study of Volociximab in Metastatic Melanoma. U.S. National Institutes of Health.
Ref 547693Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018439)
Ref 549992Phase II study of volociximab (M200), an {alpha}5?1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC), Journal of Clinical Oncology, Vol 24, No 18S (June 20 Supplement), 2006: 4535.
Ref 551212Pre-EMP-tive strike against GBM. SciBX 7(14); doi:10.1038/scibx.2014.389. April 10 2014
Ref 528465Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.
Ref 550929US patent application no. 8,541,413, Sustained release eye drop formulations.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.